SNMMI Press Releases
November 1, 2011
More Radionuclide Therapy is Better for Prostate Cancer Patients
Reston, Va. – For prostate cancer patients with bone metastases, repeated administrations of radionuclide therapy with 188Re-HEDP are shown to improve overall survival rates and reduce pain, according to new research published in the November issue of The Journal of Nuclear Medicine.
Approximately 50 percent of prostate cancer patients develop bone metastases that are predominately osteoblastic, that is, have the tendency to fracture resulting in serious morbidity. This type of bone metastasis often leads to chronic pain syndrome in prostate cancer patients; as many as 50 percent of prostate cancer patients with chronic pain syndrome are reported to receive inadequate pain treatment, which makes them candidates for radionuclide therapy.
The retrospective study, “Palliation and Survival After Repeated 188Re-HEDP Therapy of Hormone-Refractory Bone Metastases of Prostate Cancer: A Retrospective Analysis,” reviewed cases of 60 patients with hormone-refractory prostate cancer. The patients, all of whom had more than five lesions documented by a bone scan, were divided into three groups—those who received one therapy, two therapies or three or more therapies.
“Radionuclide therapy of bone metastases has been used for several decades for those with prostate cancer,” noted lead author of the study Hans-Juergen Biersack, MD. “For this study, we developed 188Re-HEDP as a novel radiopharmaceutical which—due to it is short half life of 19 hours—makes sequential therapy possible.”
The researchers found that post-treatment survival increased with the number of radionuclide therapies administered. Patients with progressive hormone-refractory prostate cancer receiving one therapy added 4.5 months, those receiving two therapies added 10 months, and those receiving three or more therapies improved their survival by 15.7 months. In addition, while the Gleason scores—a grading system used to evaluate the prognosis of men with prostate cancer—for each group were similar, the number of life-lost years for patients receiving three or more therapies was significantly lower.
In regards to pain reduction, no significant difference was found among those receiving 188Re-HEDP therapies. Pain reduction was achieved in 89.5 percent of those receiving one therapy, in 94.7 percent of those receiving two therapies and in 90.9 percent of those receiving three or more therapies.
“For patients failing chemotherapy or hormone treatments, 188Re-HEDP is a promising therapy that can both extend the number of survival years and help relieve pain from bone metastases,” noted Biersack. “The findings support and expand the role of molecular therapy with radioisotopes in oncology.”
188Re-HEDP is not commercially available and in-house production is required. 188Re-HEDP treatments for this study were developed at Oak Ridge National Laboratory in Oak Ridge, Tenn.
Authors of the article “Palliation and Survival After Repeated 188Re-HEDP Therapy of Hormone-Refractory Bone Metastases of Prostate Cancer: A Retrospective Analysis” include: Hans-Juergen Biersack, Holger Palmedo, Andrej Andris, Stefan Guhlke, Samer Ezziddin, Jan Bucerius and Dirk von Mallek, Department of Nuclear Medicine, University of Bonn, Bonn, Germany; Stefan Rogenhofer, Department of Urology, University Hospital Bonn, Bonn, Germany; and Furn F. Knapp, Nuclear Medicine Program, Oak Ridge National Laboratory, Oak Ridge, Tennessee.
Please visit the SNM Newsroom to view the PDF of the study, including images. To schedule an interview with the researchers, please contact Susan Martonik at (703) 652-6773 or email@example.com.Current and past issues of The Journal of Nuclear Medicinecan be found online at http://jnm.snmjournals.org.
About SNM—Advancing Molecular Imaging and Therapy
SNM is an international scientific and medical organization dedicated to raising public awareness about what molecular imaging is and how it can help provide patients with the best health care possible. SNM members specialize in molecular imaging, a vital element of today’s medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated.
SNM’s more than 17,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit www.snm.org.